Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

Blood-brain barrier permeability in a patient with Labrune syndrome due to SNORD118 mutations.

Taglia I, Di Donato I, De Stefano N, Bianchi S, Galluzzi P, Federico A, Dotti MT.

Eur J Neurol. 2018 Aug;25(8):e86-e87. doi: 10.1111/ene.13656. No abstract available.

PMID:
29984895
2.

Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.

Amiri H, de Sitter A, Bendfeldt K, Battaglini M, Gandini Wheeler-Kingshott CAM, Calabrese M, Geurts JJG, Rocca MA, Sastre-Garriga J, Enzinger C, de Stefano N, Filippi M, Rovira Á, Barkhof F, Vrenken H; MAGNIMS Study Group.

Neuroimage Clin. 2018 Apr 26;19:466-475. doi: 10.1016/j.nicl.2018.04.023. eCollection 2018. Review.

3.

DTI-derived indexes of brain WM correlate with cognitive performance in vascular MCI and small-vessel disease. A TBSS study.

Mascalchi M, Salvadori E, Toschi N, Giannelli M, Orsolini S, Ciulli S, Ginestroni A, Poggesi A, Giorgio A, Lorenzini F, Pasi M, De Stefano N, Pantoni L, Inzitari D, Diciotti S; VMCI-Tuscany study group.

Brain Imaging Behav. 2018 May 9. doi: 10.1007/s11682-018-9873-5. [Epub ahead of print]

PMID:
29744799
4.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

5.

Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging.

Storelli L, Rocca MA, Pagani E, Van Hecke W, Horsfield MA, De Stefano N, Rovira A, Sastre-Garriga J, Palace J, Sima D, Smeets D, Filippi M; MAGNIMS Study Group.

Radiology. 2018 Aug;288(2):554-564. doi: 10.1148/radiol.2018172468. Epub 2018 May 1.

PMID:
29714673
6.

Application of the DSM-5 Criteria for Major Neurocognitive Disorder to Vascular MCI Patients.

Salvadori E, Poggesi A, Pracucci G, Chiti A, Ciolli L, Cosottini M, Del Bene A, De Stefano N, Diciotti S, Di Donato I, Ginestroni A, Marini S, Mascalchi M, Nannucci S, Orlandi G, Pasi M, Pescini F, Valenti R, Federico A, Dotti MT, Bonuccelli U, Inzitari D, Pantoni L; VMCI-Tuscany Study Group.

Dement Geriatr Cogn Dis Extra. 2018 Mar 29;8(1):104-116. doi: 10.1159/000487130. eCollection 2018 Jan-Apr.

7.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N; Jacqueline Palace on behalf of the MAGNIMS study group.

Nat Rev Neurol. 2018 Mar 20;14(4):213. doi: 10.1038/nrneurol.2018.39.

PMID:
29582852
8.

Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.

Opfer R, Ostwaldt AC, Walker-Egger C, Manogaran P, Sormani MP, De Stefano N, Schippling S.

J Neurol. 2018 May;265(5):1158-1165. doi: 10.1007/s00415-018-8825-8. Epub 2018 Mar 16.

PMID:
29549466
9.

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

Geraldes R, Ciccarelli O, Barkhof F, De Stefano N, Enzinger C, Filippi M, Hofer M, Paul F, Preziosa P, Rovira A, DeLuca GC, Kappos L, Yousry T, Fazekas F, Frederiksen J, Gasperini C, Sastre-Garriga J, Evangelou N, Palace J; MAGNIMS study group.

Nat Rev Neurol. 2018 Apr;14(4):199-213. doi: 10.1038/nrneurol.2018.14. Epub 2018 Mar 9. Review. Erratum in: Nat Rev Neurol. 2018 Mar 20;14 (4):213.

PMID:
29521337
10.

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.

De Stefano N, Giorgio A, Tintoré M, Pia Amato M, Kappos L, Palace J, Yousry T, Rocca MA, Ciccarelli O, Enzinger C, Frederiksen J, Filippi M, Vrenken H, Rovira À; MAGNIMS study group.

Mult Scler. 2018 Feb;24(2):214-221. doi: 10.1177/1352458517717808. No abstract available.

PMID:
29451440
11.

Extracellular Vesicles from Human Liver Stem Cells Reduce Injury in an Ex Vivo Normothermic Hypoxic Rat Liver Perfusion Model.

Rigo F, De Stefano N, Navarro-Tableros V, David E, Rizza G, Catalano G, Gilbo N, Maione F, Gonella F, Roggio D, Martini S, Patrono D, Salizzoni M, Camussi G, Romagnoli R.

Transplantation. 2018 May;102(5):e205-e210. doi: 10.1097/TP.0000000000002123.

PMID:
29424767
12.

Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL-a longitudinal brain volumetry study in healthy adults.

Opfer R, Ostwaldt AC, Sormani MP, Gocke C, Walker-Egger C, Manogaran P, De Stefano N, Schippling S.

Neurobiol Aging. 2018 May;65:1-6. doi: 10.1016/j.neurobiolaging.2017.12.024. Epub 2017 Dec 30.

PMID:
29407463
13.

Deep gray matter volume loss drives disability worsening in multiple sclerosis.

Eshaghi A, Prados F, Brownlee WJ, Altmann DR, Tur C, Cardoso MJ, De Angelis F, van de Pavert SH, Cawley N, De Stefano N, Stromillo ML, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Vrenken H, Leurs CE, Killestein J, Pirpamer L, Enzinger C, Ourselin S, Wheeler-Kingshott CAMG, Chard D, Thompson AJ, Alexander DC, Barkhof F, Ciccarelli O; MAGNIMS study group.

Ann Neurol. 2018 Feb;83(2):210-222. doi: 10.1002/ana.25145. Epub 2018 Feb 6.

14.

Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.

De Stefano N, Giorgio A.

Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476. [Epub ahead of print] No abstract available.

PMID:
29308979
15.

SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI.

Battaglini M, Jenkinson M, De Stefano N; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2018 Mar;39(3):1063-1077. doi: 10.1002/hbm.23828. Epub 2017 Dec 8.

PMID:
29222814
16.

Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability.

Giorgio A, Zhang J, Stromillo ML, Rossi F, Battaglini M, Nichelli L, Mortilla M, Portaccio E, Hakiki B, Amato MP, De Stefano N.

Front Neurol. 2017 Nov 14;8:608. doi: 10.3389/fneur.2017.00608. eCollection 2017.

17.

Effective Utilization of MRI in the Diagnosis and Management of Multiple Sclerosis.

Giorgio A, De Stefano N.

Neurol Clin. 2018 Feb;36(1):27-34. doi: 10.1016/j.ncl.2017.08.013. Review.

PMID:
29157402
18.

Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.

Bovis F, De Stefano N, Steinerman JR, Knappertz V, Sormani MP.

Mult Scler. 2017 Nov 1:1352458517743804. doi: 10.1177/1352458517743804. [Epub ahead of print]

PMID:
29154721
19.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739. [Epub ahead of print]

PMID:
29143562
20.

Diffuse brain damage in normal tension glaucoma.

Giorgio A, Zhang J, Costantino F, De Stefano N, Frezzotti P.

Hum Brain Mapp. 2018 Jan;39(1):532-541. doi: 10.1002/hbm.23862. Epub 2017 Oct 24.

PMID:
29064608
21.

Imaging outcome measures for progressive multiple sclerosis trials.

Moccia M, de Stefano N, Barkhof F.

Mult Scler. 2017 Oct;23(12):1614-1626. doi: 10.1177/1352458517729456. Review.

22.

Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO.

Sormani MP, Truffinet P, Thangavelu K, Rufi P, Simonson C, De Stefano N.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 28;4(5):e379. doi: 10.1212/NXI.0000000000000379. eCollection 2017 Sep.

23.

Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials - Commentary.

De Stefano N, Giorgio A.

Mult Scler. 2017 Oct;23(11):1458-1460. doi: 10.1177/1352458517717812. Epub 2017 Jun 30. No abstract available.

PMID:
28664817
24.

Functional Evaluation of Awareness in Vegetative and Minimally Conscious State.

Marino S, Bonanno L, Ciurleo R, Baglieri A, Morabito R, Guerrera S, Rifici C, Giorgio A, Bramanti P, De Stefano N.

Open Neuroimag J. 2017 Apr 27;11:17-25. doi: 10.2174/1874440001711010017. eCollection 2017.

25.

Vitamin D levels in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).

Carluccio MA, Di Donato I, Pescini F, Battaglini M, Bianchi S, Valenti R, Nannucci S, Franci B, Stromillo ML, De Stefano N, Inzitari D, Pantoni L, Nuti R, Federico A, Gonnelli S, Dotti MT.

Neurol Sci. 2017 Jul;38(7):1333-1336. doi: 10.1007/s10072-017-2900-2. Epub 2017 Apr 4.

PMID:
28378255
26.

The spectrum of magnetic resonance findings in cerebrotendinous xanthomatosis: redefinition and evidence of new markers of disease progression.

Mignarri A, Dotti MT, Federico A, De Stefano N, Battaglini M, Grazzini I, Galluzzi P, Monti L.

J Neurol. 2017 May;264(5):862-874. doi: 10.1007/s00415-017-8440-0. Epub 2017 Mar 21.

PMID:
28324197
27.

The Italian Neuroimaging Network Initiative (INNI): enabling the use of advanced MRI techniques in patients with MS.

Filippi M, Tedeschi G, Pantano P, De Stefano N, Zaratin P, Rocca MA; INNI Network.

Neurol Sci. 2017 Jun;38(6):1029-1038. doi: 10.1007/s10072-017-2903-z. Epub 2017 Mar 14.

PMID:
28293740
28.

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.

De Stefano N, Silva DG, Barnett MH.

CNS Drugs. 2017 Apr;31(4):289-305. doi: 10.1007/s40263-017-0415-2. Review.

29.

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects.

Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M, Jouvent E, Korczyn AD, Lesnik-Oberstein SA, Malandrini A, Markus HS, Pantoni L, Penco S, Rufa A, Sinanović O, Stojanov D, Federico A.

BMC Med. 2017 Feb 24;15(1):41. doi: 10.1186/s12916-017-0778-8. Review.

30.

The role of dentate nuclei in human oculomotor control: insights from cerebrotendinous xanthomatosis.

Rosini F, Pretegiani E, Mignarri A, Optican LM, Serchi V, De Stefano N, Battaglini M, Monti L, Dotti MT, Federico A, Rufa A.

J Physiol. 2017 Jun 1;595(11):3607-3620. doi: 10.1113/JP273670. Epub 2017 Mar 14.

31.

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.

De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.

Mult Scler. 2018 Feb;24(2):222-226. doi: 10.1177/1352458517690269. Epub 2017 Jan 31.

32.

Resting state fMRI regional homogeneity correlates with cognition measures in subcortical vascular cognitive impairment.

Diciotti S, Orsolini S, Salvadori E, Giorgio A, Toschi N, Ciulli S, Ginestroni A, Poggesi A, De Stefano N, Pantoni L, Inzitari D, Mascalchi M; VMCI Tuscany investigators.

J Neurol Sci. 2017 Feb 15;373:1-6. doi: 10.1016/j.jns.2016.12.003. Epub 2016 Dec 6.

PMID:
28131162
33.

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study.

Comi G, De Stefano N, Freedman MS, Barkhof F, Uitdehaag BM, de Vos M, Marhardt K, Chen L, Issard D, Kappos L.

J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):285-294. doi: 10.1136/jnnp-2016-314843. Epub 2016 Dec 30.

34.

Brain MRI atrophy quantification in MS: From methods to clinical application.

Rocca MA, Battaglini M, Benedict RH, De Stefano N, Geurts JJ, Henry RG, Horsfield MA, Jenkinson M, Pagani E, Filippi M.

Neurology. 2017 Jan 24;88(4):403-413. doi: 10.1212/WNL.0000000000003542. Epub 2016 Dec 16. Review.

35.

Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study.

Damjanovic D, Valsasina P, Rocca MA, Stromillo ML, Gallo A, Enzinger C, Hulst HE, Rovira A, Muhlert N, De Stefano N, Bisecco A, Fazekas F, Arévalo MJ, Yousry TA, Filippi M.

AJNR Am J Neuroradiol. 2017 Jan;38(1):18-24. doi: 10.3174/ajnr.A4952. Epub 2016 Sep 29.

36.

Early changes of brain connectivity in primary open angle glaucoma.

Frezzotti P, Giorgio A, Toto F, De Leucio A, De Stefano N.

Hum Brain Mapp. 2016 Dec;37(12):4581-4596. doi: 10.1002/hbm.23330. Epub 2016 Aug 9.

PMID:
27503699
37.

A Semiautomatic Method for Multiple Sclerosis Lesion Segmentation on Dual-Echo MR Imaging: Application in a Multicenter Context.

Storelli L, Pagani E, Rocca MA, Horsfield MA, Gallo A, Bisecco A, Battaglini M, De Stefano N, Vrenken H, Thomas DL, Mancini L, Ropele S, Enzinger C, Preziosa P, Filippi M.

AJNR Am J Neuroradiol. 2016 Jul 21. [Epub ahead of print]

PMID:
27444938
38.

Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.

Sormani MP, Kappos L, Radue EW, Cohen J, Barkhof F, Sprenger T, Piani Meier D, Häring D, Tomic D, De Stefano N.

Mult Scler. 2017 Apr;23(5):656-664. doi: 10.1177/1352458516659550. Epub 2016 Jul 18.

PMID:
27411701
39.

Relationship of white and gray matter abnormalities to clinical and genetic features in myotonic dystrophy type 1.

Zanigni S, Evangelisti S, Giannoccaro MP, Oppi F, Poda R, Giorgio A, Testa C, Manners DN, Avoni P, Gramegna LL, De Stefano N, Lodi R, Tonon C, Liguori R.

Neuroimage Clin. 2016 May 3;11:678-85. doi: 10.1016/j.nicl.2016.04.012. eCollection 2016.

40.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
41.

Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.

De Stefano N, Tomic D, Radue EW, Sprenger T, Meier DP, Häring D, Sormani MP.

Mult Scler Relat Disord. 2016 May;7:98-101. doi: 10.1016/j.msard.2016.03.017. Epub 2016 Mar 31.

PMID:
27237768
42.

Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series.

Cantarini L, Stromillo ML, Vitale A, Lopalco G, Emmi G, Silvestri E, Federico A, Galeazzi M, Iannone F, De Stefano N.

Isr Med Assoc J. 2016 Mar-Apr;18(3-4):238-42.

43.

MRI monitoring of spinal cord changes in patients with multiple sclerosis.

Rovira A, de Stefano N.

Curr Opin Neurol. 2016 Aug;29(4):445-52. doi: 10.1097/WCO.0000000000000343. Review.

PMID:
27175890
44.

Advanced Structural and Functional Brain MRI in Multiple Sclerosis.

Giorgio A, De Stefano N.

Semin Neurol. 2016 Apr;36(2):163-76. doi: 10.1055/s-0036-1579737. Epub 2016 Apr 26. Review.

PMID:
27116723
45.

A practical review of the neuropathology and neuroimaging of multiple sclerosis.

Matthews PM, Roncaroli F, Waldman A, Sormani MP, De Stefano N, Giovannoni G, Reynolds R.

Pract Neurol. 2016 Aug;16(4):279-87. doi: 10.1136/practneurol-2016-001381. Epub 2016 Mar 23. Review.

PMID:
27009310
46.

Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study.

Preziosa P, Rocca MA, Pagani E, Stromillo ML, Enzinger C, Gallo A, Hulst HE, Atzori M, Pareto D, Riccitelli GC, Copetti M, De Stefano N, Fazekas F, Bisecco A, Barkhof F, Yousry TA, Arévalo MJ, Filippi M; MAGNIMS Study Group.

Hum Brain Mapp. 2016 Apr;37(4):1627-44. doi: 10.1002/hbm.23125. Epub 2016 Feb 2.

PMID:
26833969
47.

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.

Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintorè M, Frederiksen JL, Gasperini C, Palace J, Reich DS, Banwell B, Montalban X, Barkhof F; MAGNIMS Study Group.

Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26. Review.

48.

Alterations in Functional and Structural Connectivity in Pediatric-Onset Multiple Sclerosis.

Akbar N, Giorgio A, Till C, Sled JG, Doesburg SM, De Stefano N, Banwell B.

PLoS One. 2016 Jan 5;11(1):e0145906. doi: 10.1371/journal.pone.0145906. eCollection 2016.

49.

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. Review.

50.

Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.

Kantarci OH, Lebrun C, Siva A, Keegan MB, Azevedo CJ, Inglese M, Tintoré M, Newton BD, Durand-Dubief F, Amato MP, De Stefano N, Sormani MP, Pelletier D, Okuda DT.

Ann Neurol. 2016 Feb;79(2):288-94. doi: 10.1002/ana.24564. Epub 2015 Dec 29.

PMID:
26599831

Supplemental Content

Loading ...
Support Center